A “game-changing” antiviral pill that is part of the AGILE … Continued
A new international trial to assess whether high doses of … Continued
LIVERPOOL, England, 20 April 2021 — The University of Liverpool, Liverpool School of Tropical Medicine, and the NIHR Southampton Clinical Trials Unit at the University of Southampton today announced the first-ever patient dosed in the latest trial of potential new treatments for SARS-CoV-2 as part of the UK’s COVID-19 drug testing platform, AGILE.
Take a look at this case study from @Medidata who are supporting @SouthamptonCTU with the AGILE clinical trial platform #COVID19 #clinicaltrials
The Liverpool Drug Interactions website team developed a freely available drug interactions resource to provide information on the likelihood of interactions between the experimental agents used for the treatment of COVID-19 and commonly prescribed co-medications.
Find out more here.